Objective. The need for public health laboratories (PHLs) to prioritize resources has led to increased interest in sharing diagnostic services. To address this concept for tuberculosis (TB) testing, the New York State Department of Health Wadsworth Center and the Rhode Island State Health Laboratories assessed the feasibility of shared services for the detection and characterization of Mycobacterium tuberculosis complex (MTBC).
Results. Testing turnaround times were similar at both PHLs; however, the availability of conventional drug susceptibility testing (DST) results for Rhode Island primary specimens and isolates were extended by approximately four days of shipping time. An extended molecular testing panel was performed on every specimen submitted from Rhode Island State Health Laboratories to Wadsworth Center, and the total cost per specimen at Wadsworth Center was $177.12 less than at Rhode Island State Health Laboratories, plus shipping. Following a mid-study review, Wadsworth Center provided testing turnaround times for detection (same day), species determination of MTBC (same day), and molecular DST (2.5 days).
Conclusion. The collaboration between Wadsworth Center and Rhode Island
State Health Laboratories to assess shared services of TB testing highlighted a successful model that may serve as a guideline for other PHLs. The provision of additional rapid testing at a lower cost demonstrated in this study could potentially improve patient management and result in significant cost and resource savings if used in similar models across the country.
Public health laboratories (PHLs) are essential for disease prevention and control. They serve as a first line of defense by rapidly recognizing and averting the spread of communicable diseases. In addition, they play a critical role in providing specialized tests for low-incidence, high-risk diseases, such as tuberculosis (TB), rabies, and botulism. 1 Due to recent economic constraints, many PHLs have suffered financial pressures, including budget and staffing cuts. In some cases, PHLs have reduced or eliminated certain tests, creating a potential risk to the public's health. As an alternative to the discontinuation of services, one suggested approach was the investigation of shared services with other PHLs in different jurisdictions through testing directories and pilot projects with assistance and support from the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL). 2, 3 TB, which is caused by the bacteria Mycobacterium tuberculosis, is a disease for which PHLs play an important role by providing diagnostics that contribute to prevention. Despite an overall decline in cases, TB continues to be a significant burden on social, public health, and economic systems in the United States. 4 Maintaining a comprehensive and efficient laboratory system is critical to the continued decline of TB rates and overall prevention and control of TB in the United States. However, providing comprehensive TB testing services is becoming increasingly expensive per case identified. Additionally, retaining technical proficiency remains a challenge, especially as many experienced personnel are lost to retirement and are difficult to replace. 5 In 2013, a total of 9,582 new TB cases were reported in the United States, with an incidence rate of 3.0 cases per 100,000 population. Only four states reported more than 500 cases of TB: California, Texas, New York, and Florida, accounting for half of all TB cases in the United States. The TB incidence rate in New York State (NYS) is 4.4 per 100,000 population. 4 The overall number of TB cases in NYS has decreased slightly over time, while the number of drug-resistant TB (DR TB) cases has remained steady during the past five years. Additionally, the percentage of multidrug-resistant TB (MDR TB) cases in NYS has increased from 1.3% to 3.6% during the past five years. 6 In contrast, the TB incidence rate in Rhode Island is 2.6 per 100,000 population, and the overall number of TB cases has remained constant; DR TB and MDR TB cases in Rhode Island are rare. 4, 7 Given the low number of TB-positive specimens received each year in Rhode Island State Health Laboratories, developing an extensive, increasingly molecular-based, testing program for TB may not be cost effective. In contrast, a high proportion of specimens received each year by the NYS Department of Health Wadsworth Center are Mycobacterium tuberculosis complex (MTBC) positive, including DR TB and MDR TB cases, and an extensive testing program has been implemented.
We assessed the feasibility of shared services for the detection and characterization of MTBC between Wadsworth Center and Rhode Island State Health Laboratories during a 10-month time period. Multiple aspects critical to the implementation of shared services were examined, including shipping, testing, reporting, and cost. During this project, Wadsworth Center provided services to Rhode Island State Health Laboratories for rapid detection of MTBC, MTBC species identification, rapid detection of mutations associated with rifampin and isoniazid resistance, and conventional drug susceptibility testing (DST). Importantly, this partnership allowed Wadsworth Center to assess its ability to share its extended testing capabilities with another PHL, determine if the additional services provided were beneficial to patient treatment and outcomes, and identify any potential issues with this testing approach.
METHODS

Specimen requirements
For this study, Rhode Island State Health Laboratories submitted two types of specimens to Wadsworth Center: (1) acid-fast bacilli isolates testing positive for MTBC by the AccuProbe culture identification test (Hologic, Bedford, Massachusetts) and (2) primary clinical specimens testing positive for MTBC by nucleic acid amplification testing using a laboratory-developed test. Importantly, during the course of this project, all specimens continued to be tested in parallel in Rhode Island following Rhode Island State Health Laboratories testing algorithms.
Study evaluation
Phase 1 of the study was performed from August 2012 to January 2013, and phase 2 of the study was performed from February through June 2013. Shipping, testing, and reporting times were monitored throughout the study. At six months, areas for improvement were identified and changes were implemented accordingly. Overall turnaround times were calculated before and after these changes from the date of first MTBC-positive result in Rhode Island to final report.
Shipping
All specimens were shipped overnight at ambient temperature immediately after an MTBC-positive result at Rhode Island State Health Laboratories. This shipping practice, the establishment of a FedEx ® account for Rhode Island State Health Laboratories, and the provision of mailers were important to minimize the time between testing performed at each site. Shipping turnaround times were calculated from the date of first MTBC-positive result in Rhode Island to date of specimen accessioning at Wadsworth Center.
Testing
A primary focus of this study was to address the impact of shared services on TB testing practices. We examined the ability to achieve shared services for detecting and identifying MTBC species, detecting mutations associated with drug resistance, and conventional DST. At the start of this study, all primary specimens and isolates received from Rhode Island State Health Laboratories were tested according to the routine Wadsworth Center testing algorithm ( Figure) . Briefly, the specimen was confirmed MTBC positive by real-time polymerase chain reaction (PCR), 8 smear microscopy was performed, and both liquid and solid cultures were inoculated. All specimens were tested using realtime PCR regardless of the smear result. Samples were then tested using a multiplex real-time assay for MTBC species identification. 9 Additionally, pyrosequencing of rpoB, katG, and inhA genes (molecular DST) were batched and performed weekly to detect mutations associated with drug resistance to rifampin and isoniazid. 10 Finally, conventional first-line DST using the BACTEC™ MGIT™ 960 SIRE kit (Becton Dickinson and Co., Franklin Lakes, New Jersey) was performed to determine susceptibility to streptomycin, isoniazid, rifampin, and ethambutol. DST was performed in liquid medium within five days of initial positivity of the primary mycobacterial growth indicator tables culture.
To improve testing turnaround times, the molecular testing algorithm was modified after phase 1 (Figure) . Modifications included performing MTBC detection and MTBC species identification on the same day of specimen receipt. Additionally, molecular DST was set up and performed the following day for all specimens rather than batched weekly. Importantly, throughout this collaboration, the TB testing capacity at Rhode Island State Health Laboratories remained unchanged and followed existing testing algorithms.
Reporting
All results were reported and retrieved electronically using the Wadsworth Center Clinical Laboratory Information Management System (CLIMS), via the NYS Health Provider Network. With this system, results are available in real time, as they are released, and can be accessed seven days per week. At the beginning of the study, Rhode Island State Health Laboratories became a registered submitter with NYS to be able to retrieve the results remotely from any location. Reporting turnaround times were calculated from the date testing was completed to the date test results were reported via CLIMS/NYS Health Provider Network, or mailed prior to set-up of this system in Rhode Island.
Cost analysis
Cost analysis was performed to determine and compare the cost per specimen for each test in both laboratories as others have calculated. 11 The average cost per specimen for testing was calculated based on laboratory purchase requisitions during the 10-month time period. The cost of running controls and repeat testing were factored in using the following equation 
RESULTS
Shipping
We summarized the overall turnaround times for shipping of all primary specimens and isolates (Table 1) . During phase 1, Wadsworth Center accessioned a total of nine specimens, with an average turnaround time of four days. Two of the four days were transit time; however, the other two days were due to issues at one or both sites, which led to an overall increase in the average shipping turnaround time. Several areas for improvement were identified. The most common issue for the submitting laboratory was obtaining testing results late in the day, which
delayed shipment of the specimen to the following day and contributed to the average turnaround time. Also, if a specimen was determined to be MTBC positive late on a Friday afternoon, it was not received at Wadsworth Center until Monday morning. For the receiving laboratory, the most common delay was that specimens were received after the daily accessioning was performed. Other minor issues that resulted in shipping delays included loss of paperwork, unsatisfactory specimen volume, and miscommunication between the laboratories. After identifying these issues, the most significant modification was to delay specimen accessioning and testing at Wadsworth Center on days when a specimen was expected from Rhode Island State Health Laboratories until all morning deliveries were finalized. The shipping turnaround time decreased to approximately three days following implementation of these changes in phase 2 (Figure) . Although the changes reduced shipping turnaround times by a full day, the transit time remained the same.
Testing
During phase 1, nine specimens were received, comprising one primary clinical specimen and eight isolates. Following the testing algorithm ( Figure) , the average testing turnaround times were 1.5 days from receipt in NYS to MTBC detection with real-time PCR, 3.5 days for MTBC species identification, 7.0 days for molecular DST, and 23.0 days for conventional first-line DST ( Table 1) . Data analysis identified molecular testing services as an area in which turnaround times could be reduced, as these testing methods were not dependent on the rate of culture growth. Consequently, the molecular testing algorithm was modified for all primary specimens and isolates received from Rhode Island (Figure) . During phase 2, nine additional specimens were received, comprising four primary clinical specimens and five isolates. Following the modified testing algorithm, average turnaround times improved significantly to same day as receipt for both MTBC detection and MTBC species identification and 2.5 days for molecular DST (Table 1) .
Reporting
During phase 1 of the study, the average reporting turnaround time was two days. These turnaround times were higher than anticipated; however, during this time, Rhode Island State Health Laboratories was not fully set up for the electronic reporting system and results were being transmitted via fax or regular mail. Once the reports became available electronically through CLIMS, reporting turnaround times were the same day as the results were generated (Table 1) .
Cost analysis
The average testing costs were calculated at both state PHLs. Overall testing costs were significantly lower at Wadsworth Center ($199.00) than at Rhode Island State Health Laboratories ($376.12) per MTBC-positive specimen. Shipping charges were accounted for separately, and the average cost was $65.00 per specimen ( Table 2) .
DISCUSSION
Beginning in early 2011, CDC and APHL launched the Laboratory Efficiencies Initiative to help the nation's PHL system achieve and maintain sustainability and to continue conducting vital services in the face of unprecedented financial constraints. 3 Organization and sharing of laboratory testing services was listed as one key strategy in this document. Regionalized testing services for TB have the potential to reduce costs while maintaining and expanding testing for patients. This study serves as a foundation for future models of shared services that can be used by PHLs across the country. It suggests that shared services would have a positive impact on patient care.
In our study, culture and susceptibility testing turn-around times were similar in both laboratories and reports were generated and received the same day. Notably, after improving the testing algorithms during phase 2 of the study, Wadsworth Center was able to provide confirmation of MTBC and MTBC species identification on the same day of receipt and molecular DST results within 2.5 days of receipt. While testing turnaround times were similar for conventional DST, the availability of test results from Wadsworth Center was delayed by four days compared with Rhode Island exclusively due to time required for shipping. In the future, faster turnaround times could also be achieved by not confirming MTBC and by sending specimens directly to molecular and conventional DST. Nonetheless, this study demonstrated that a PHL in a state with a low number of TB-positive specimens could benefit by working with a larger laboratory, such as Wadsworth Center, where more testing services are offered. Future implementation of shared testing services will need to consider shipping delays as well as specimen testing prioritization and management of outbreak investigations.
Additionally, this study showed that using an electronic reporting system allowed for same-day reporting of all testing results. However, while utilizing this reporting system was beneficial for this study, it may not be the ideal solution; integrating laboratory information management systems between state PHLs may be more useful. In the future, reporting delays could be avoided by deploying an implementation process for setup in advance and including training and support for the electronic reporting system. In addition, new regulations under the Affordable Care Act mandate improvements for electronic reporting of laboratory tests, and reporting systems such as the network used by the Wadsworth Center may serve as a model in the future. 12 Overall, our data indicated that patient outcome, particularly for MDR TB patients, may benefit from a shared services approach and may represent an alternate testing solution for the future.
Benefits for patient management resulting from the broader testing at Wadsworth Center were illustrated by the following example. One Rhode Island patient was infected with Mycobacterium bovis (M. bovis), which was identified by Wadsworth Center within one day of specimen receipt. This patient was positively impacted as pyrazinamide was removed from the treatment based on the known M. bovis natural resistance to this drug. 13 While there were no other examples of drug resistance during this study, rapid diagnostic methods, such as early detection of mutations associated with drug resistance, would undoubtedly improve TB patient management in Rhode Island or other states where such testing is not currently offered.
Shipping remains an area in need of optimization. Preparation of specimens for shipping, transit time, and accessioning time at Wadsworth Center amounted to a delay in obtaining conventional DST results. Additionally, shipping may also compromise the viability of MTBC in the specimens. During the course of this study, we encountered two MTBC-positive primary specimens that did not grow in culture at Wadsworth Center. This issue may have been circumstantial due to decreased volume of culture inoculum resulting from a low specimen quantity received. Another possible explanation is decreased specimen viability after a few days in transit. Therefore, implementation of shared services for TB should include further evaluation of shipping times and specimen conditions to provide the best possible culture results.
In comparing the estimated specimen testing costs between the two states, the most notable difference was in the number of molecular tests that can be provided for a lower cost in a larger state PHL. The overall savings can be attributed to the ability to purchase consumables in bulk combined with a larger testing volume and higher MTBC positivity rate. In addition, larger PHLs have the ability to develop their own tests, which can provide substantial cost savings compared with the commercially available U.S. Food and Drug Administration-approved tests, such as Hologic Amplified MTD and Xpert ® MTB/RIF (Cepheid, Sunnyvale, California), and tests can be tailored to laboratory-specific needs. Individual laboratories should evaluate the cost of these commercially available assays compared with laboratory-developed assays based upon their own testing algorithms and the number of specimens tested. Furthermore, many larger laboratories have access to in-house core services producing some of the media reagents that can also contribute to the reduction of culture-related expenses. The higher cost of testing a small number of MTBC-positive specimens in Rhode Island would have to be weighed against increased overall turnaround time to obtain the lower cost result from the Wadsworth Center. Due to the nature of the study, shipping costs were not added to the submitting laboratories' total cost. However, overall shipping cost should be an important consideration for future implementation and may vary substantially throughout the country based upon transportation costs and overall shipping distance.
This cost analysis suggests that shared services provide more comprehensive testing on positive specimens for a reduced cost. Cost was not compared for negative specimens. Finally, the cost of maintaining competency, proficiency testing, and staff time in each Other concerns not addressed in this study but that need to be considered include the differing laws governing state PHLs and state testing regulations. In 2012, CDC and APHL published two documents providing guidance to PHL directors and their legal counsel regarding state and federal laws, which may be implicated in shared testing services. 14, 15 States may have regulations requiring the state PHL to perform all testing, requiring authorization for contractual arrangements for all or certain aspects of testing services, or allowing out-of-state specimen testing. Specifically, Rhode Island state public health laws require all TB testing to be performed at the state health laboratories and a few designated in-state hospital laboratories. 16 Another aspect to be evaluated is laboratory certification requirements. The Clinical Laboratory Improvement Amendments of 1988 set forth conditions that all laboratories must meet to be certified to perform testing on human specimens for the diagnosis, prevention, or treatment of disease. 17 However, states may have their own additional mandated requirements. For example, NYS has an additional laboratory regulatory program, the Clinical Laboratory Evaluation Program, which mandates that all NYS patient specimens must be tested using U.S. Food and Drug Administrationapproved or laboratory-developed tests that have been sufficiently validated. The protocols and validation data must be submitted, reviewed, and approved by subject matter experts within the Clinical Laboratory Evaluation Program, regardless of the state in which the testing is performed. 18 CONCLUSION While many aspects of shared services still need to be investigated, the partnership between Rhode Island State Health Laboratories and Wadsworth Center proved valuable for both laboratories. The main benefit for Rhode Island State Health Laboratories was that their specimens underwent more extensive testing compared with what is offered in Rhode Island. Information obtained from this additional testing had the potential to improve patient care, especially in the early identification of MDR TB. For Wadsworth Center, the additional specimens received were a low burden for laboratory staff. Furthermore, Wadsworth Center had the opportunity to examine its current testing algorithms and turnaround times and identify areas where testing could be improved or expanded in the future. Overall, this collaboration highlights a successful model that can serve as a guideline for PHLs across the country. This work was supported by the Association of Public Health Laboratories (APHL) and by cooperative agreement #U60HM000803 from the Centers for Disease Control and Prevention (CDC) and/or Assistant Secretary for Preparedness and Response for "Exploring Novel Approaches to Shared TB Laboratory Services." The findings and conclusions in this article are those of the authors and do not necessarily represent the views of CDC or APHL.
